Latest Content

TAR-200 Shows High Response Rates in Bladder Cancer Subset

April 29th 2025, 7:00pm

By Kyle Doherty

Article

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study.

A Fellow Cancer Survivor Gives Me a Useful Message

April 29th 2025, 5:00pm

By Laura Yeager

Article

A chance meeting with my childhood friend reminded me — and others — that living with cancer means taking things one day at a time.

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

April 29th 2025, 4:04pm

By Spencer Feldman

Article

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.

FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer

April 29th 2025, 3:00pm

By Spencer Feldman

Article

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.

SIRT With 90Y Resin Microspheres Provides Benefit in GIST Liver Metastases

April 29th 2025, 1:00pm

By Spencer Feldman

Article

SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver metastases resistant to TKI therapy.

Alternating Glivec and Stivarga Doesn't Improve Advanced GIST Outcomes

April 28th 2025, 9:00pm

By Ryan Scott

Article

Alternating between Glivec and Stivarga therapy didn't impact survival outcomes; it led to more toxicity and discontinuations in patients with GIST.

Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients

April 28th 2025, 8:00pm

By Dr. Pouneh Razavi

Video

Breast MRI helps doctors detect disease in newly diagnosed and high-risk patients without replacing mammograms, according to an expert.

Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer

April 28th 2025, 7:00pm

By Jax DiEugenio

Article

Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety.

How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer

April 28th 2025, 5:00pm

By Felicia Mitchell

Article

I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.

TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups

April 28th 2025, 4:00pm

By Ryan Scott

Article

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.

Zongertinib Elicits Responses in HER2-Mutant NSCLC

April 28th 2025, 3:00pm

By Alex Biese

Article

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.

How an Advocate Unites Voices to Guide MPN Research Decisions

April 28th 2025, 1:00pm

By Richard Winneker

Video

Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.

Healer, Mentor and Leader

April 27th 2025, 6:00pm

By Susie Maloney, M.S., APRN, AOCN, AOCNS

Article

Reflecting upon my relationship with Jill over the past 25 years, I am in awe of all she has accomplished.

Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models

April 27th 2025, 6:00pm

By Ryan Scott

Article

HT-KIT, a novel targeted therapy for GIST, demonstrated the ability to reduce tumor burden in humanized mouse models and induce tumor cell death.

FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors

April 26th 2025, 6:00pm

By Spencer Feldman

Article

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.